MedTrace Logo

Study Evaluating Intravitreal hI-con1™ in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration

NCT02358889 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 88

Last updated 2020-09-24

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the safety, biological activity and pharmacodynamic effect of repeated intravitreal doses of hI-con1 0.3 mg administered as monotherapy and in combination with ranibizumab 0.5 mg compared to ranibizumab 0.5 mg monotherapy in treating patients with choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD).

Conditions

  • Choroidal Neovascularization
  • Age-related Macular Degeneration

Interventions

BIOLOGICAL

hI-con1

Intravitreal injection of hI-con1 0.3 mg

BIOLOGICAL

ranibizumab

Intravitreal injection of ranibizumab 0.5 mg

OTHER

Sham injection

No injection is given, a needleless syringe is used to mimic an injection.

Sponsors & Collaborators

  • Iconic Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Gabriela Burian, MD · Iconic Therapeutics, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-02-28
Primary Completion
2016-09-30
Completion
2016-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02358889 on ClinicalTrials.gov